NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

First, it is an editorial and it is not a peer-reviewed paper.

Second, both authors failed to mention they received funding from Novocure. Also Martin J. van den Bent and the editor-in-chief Susan Chang have been funded by Agios which is developing a drug on IDH1-mutant glioblastoma.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546125/